Approval · Notice of Compliance 3962 · 1997
LEUCOMAX: Notice of Compliance 3962
Issued March 10, 1997
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 3962
- Date
- March 10, 1997
- Company
- Schering Canada Inc.
- Product type
- Biologic
- Submission
- New Drug Submission (NDS)
- Submission class
- Priority-NAS
- Therapeutic class
- Hematopoietic growth factor
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| LEUCOMAX | 02230921 | — |
| LEUCOMAX | 02230922 | — |
| LEUCOMAX | 02230923 | — |
| LEUCOMAX | 02230924 | — |
Medicinal ingredients
- MOLGRAMOSTIM 150 MCG per VIAL
- MOLGRAMOSTIM 300 MCG per VIAL
- MOLGRAMOSTIM 400 MCG per VIAL
- MOLGRAMOSTIM 700 MCG per VIAL